Trials / Completed
CompletedNCT01302860
Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease
A One-year Open-label, Multicenter Trial to Assess Efficacy, Safety and Tolerability of Canakinumab (ACZ885) and the Efficacy and Safety of Childhood Vaccinations in Patients Aged 4 Years or Younger With Cryopyrin Associated Periodic Syndromes (CAPS)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 1 Month – 60 Months
- Healthy volunteers
- Not accepted
Summary
This trial will assess the safety, efficacy and tolerability of ACZ885 in patients aged 4 years and younger with cryopyrin associated periodic syndromes (CAPS)
Conditions
- Cryopyrin-associated Periodic Syndromes
- Familial Cold Autoinflammatory Syndrome
- Muckle-Wells Syndrome
- Neonatal Onset Multisystem Inflammatory Disease
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ACZ885 |
Timeline
- Start date
- 2010-11-01
- Primary completion
- 2014-11-01
- Completion
- 2014-11-01
- First posted
- 2011-02-24
- Last updated
- 2017-03-29
- Results posted
- 2015-08-18
Locations
12 sites across 7 countries: Belgium, Canada, France, Germany, Spain, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT01302860. Inclusion in this directory is not an endorsement.